Acetaminophen And Oxycodone

Introduction Overview

Generic Name

acetaminophen and oxycodone

Brand Name

Percocet

Dosage Form

Oral tablet

Drug Class

Narcotic analgesic combinations

Pharmacokinetics

Absorption:
Percocet contains oxycodone, a rapidly absorbed opioid analgesic, and acetaminophen, a non-opioid analgesic. Upon oral administration, oxycodone is well absorbed through the gastrointestinal tract, with peak plasma concentrations typically reached within 1 hour. Acetaminophen is also rapidly absorbed with peak plasma levels generally attained within 30 to 60 minutes. The combination of oxycodone and acetaminophen results in synergistic analgesic effects. Factors such as food intake may slightly delay oxycodone absorption but do not significantly affect overall bioavailability. The extent of absorption for both components is high, but oxycodone exhibits first-pass metabolism that reduces its bioavailability to approximately 60-87%, whereas acetaminophen has nearly complete bioavailability.

Distribution:
Oxycodone is widely distributed throughout body tissues, including the central nervous system (CNS). It is approximately 38-45% bound to plasma proteins, mainly albumin, while acetaminophen exhibits low plasma protein binding (~20%). Oxycodone crosses the blood-brain barrier effectively, which is critical to its analgesic action at opioid receptors in the CNS. The volume of distribution for oxycodone is approximately 2.6 L/kg, indicating widespread tissue penetration. Acetaminophen distributes rapidly into most body fluids and tissues but does not significantly concentrate in fat. Both drugs can cross the placenta, and oxycodone is excreted in breast milk, posing risks to neonates.

Metabolism:
Oxycodone undergoes extensive hepatic metabolism primarily via the cytochrome P450 enzyme system, mainly CYP3A4 and CYP2D6 isoenzymes. CYP3A4 mediates N-demethylation to noroxycodone, an inactive metabolite, and CYP2D6 mediates O-demethylation to oxymorphone, an active metabolite with potent analgesic effects. Genetic polymorphisms in CYP2D6 can influence individual patient metabolism and response. Acetaminophen is metabolized in the liver predominantly via conjugation pathways forming inactive glucuronide and sulfate metabolites. A small fraction undergoes oxidation by CYP2E1 producing the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is detoxified by glutathione. Overdose of acetaminophen can deplete glutathione and cause hepatic injury.

Elimination:
The elimination half-life of oxycodone is approximately 3.5 to 4 hours in healthy adults. Its metabolites and unchanged drug are primarily eliminated by renal excretion. Approximately 10% of oxycodone is excreted unchanged in urine. Acetaminophen has a half-life of approximately 2 to 3 hours and is almost entirely eliminated via renal excretion of its conjugates. Impairment of renal or hepatic function can prolong the elimination half-life of both components, necessitating dosage adjustment. Due to the risk of accumulation and toxicity, especially acetaminophen-induced hepatotoxicity, careful monitoring during extended therapy or in patients with compromised liver function is essential.

Dosage Forms

Available Dosage Forms:
Percocet is available as oral tablets combining oxycodone and acetaminophen. The commonly available strengths include tablets containing oxycodone 2.5 mg, 5 mg, 7.5 mg, or 10 mg combined with acetaminophen 325 mg.

Dosages for Adults and Adolescents:
The usual adult dosage for Percocet is 1 to 2 tablets taken every 4 to 6 hours as needed for pain. The total acetaminophen dose should not exceed 4000 mg per day to avoid hepatotoxicity. In cases of severe pain, the upper oxycodone dose may be titrated carefully based on efficacy and tolerability. Pediatric use under 18 years of age is generally not recommended due to safety concerns with oxycodone.

Specific Patient Populations:
In patients with hepatic or renal impairment, reduced dosages or careful monitoring is recommended because of the decreased metabolism and elimination of oxycodone and acetaminophen. Elderly or debilitated patients may require lower doses due to increased risk of sedation and respiratory depression. Percocet is contraindicated in patients with severe respiratory depression or acute/severe bronchial asthma. Pregnant women should use Percocet only if clearly needed, due to risk of neonatal opioid withdrawal syndrome. Breastfeeding is not recommended during treatment.

Clinical Guidelines:
Percocet should be reserved for moderate to severe pain where non-opioid therapies have failed or cannot be tolerated. Chronic use requires close monitoring to prevent misuse, addiction, respiratory depression, and acetaminophen-induced liver damage.

Mechanism Of Action

Percocet combines two analgesic agents, oxycodone and acetaminophen, which exert distinct yet complementary mechanisms of action resulting in enhanced pain relief. Oxycodone is a semisynthetic opioid agonist predominantly targeting the mu-opioid receptors located in the central nervous system. Binding to these G-protein-coupled receptors leads to inhibition of adenylate cyclase activity, decreased intracellular cAMP levels, and the opening of potassium channels causing neuronal hyperpolarization. This cascade inhibits the release of neurotransmitters such as substance P, glutamate, and calcitonin gene-related peptide involved in pain transmission, thereby attenuating nociceptive signal propagation.

Acetaminophen’s precise mechanism is not fully elucidated but is believed to involve central inhibition of cyclooxygenase (COX) enzymes, particularly COX-3 isoform in the brain, which reduces prostaglandin synthesis responsible for pain sensitization and fever. Unlike nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen has minimal peripheral anti-inflammatory activity. There is also evidence that acetaminophen acts through the serotonergic descending inhibitory pain pathways and may modulate the endocannabinoid system enhancing analgesia.

Clinically, the combination leverages oxycodone’s potent opioid receptor-mediated analgesia with acetaminophen’s central modulation of pain and temperature, allowing for efficacy at lower opioid doses. This synergistic interaction improves pain control and potentially reduces opioid-related adverse effects. Comparative studies show that the combination provides superior relief for moderate to severe pain compared to either component alone.

Research supports that oxycodone’s metabolism to active oxymorphone contributes to its analgesic profile and pharmacogenomic variability influences patient response. Ongoing investigations explore novel mechanisms of acetaminophen linked to nitric oxide pathways and antioxidant effects. Collectively, Percocet offers effective analgesia suitable for post-surgical pain, injury, and other acute pain conditions but must be used cautiously due to opioid dependence risk.

Pharmacological Actions

Mu-opioid receptor agonism by oxycodone producing analgesia.
Central nervous system depression causing sedation and respiratory depression.
Inhibition of prostaglandin synthesis in the CNS by acetaminophen leading to analgesic and antipyretic effects.
Synergistic analgesic effect due to combination of opioid and non-opioid mechanisms.
Modulation of neurotransmitter release reducing neuronal excitability and pain signal transmission.
Minimal anti-inflammatory activity due to acetaminophen’s central, not peripheral, action.
Effect on serotonergic descending pain pathways enhancing analgesia.
Potential effect on endocannabinoid system contributing to pain relief.
Metabolite oxymorphone contributes to overall opioid analgesic efficacy.
Opioid-induced euphoria and mood alteration via CNS effects.
Suppression of cough reflex through opioid action on medullary cough center.
Reduction in gastrointestinal motility resulting in constipation.

Therapeutic Or Clinical Uses

Management of moderate to severe acute pain where non-opioid analgesics are insufficient.
Postoperative pain control following surgeries of varied complexity.
Pain relief associated with trauma or injury.
Adjunct therapy for chronic pain when other treatments are inadequate and benefits outweigh risks.
Short-term pain management for musculoskeletal conditions.
Treatment of pain in cancer patients requiring opioid analgesia.
Analgesia in patients intolerant to other opioid preparations.
Palliative care to improve quality of life in advanced illnesses.
Management of dental pain following procedures.
Use in controlled settings for breakthrough pain episodes.
Treatment of pain in patients without history of opioid misuse or addiction.

Side Or Adverse Effects

Dizziness and sedation due to CNS depression from oxycodone.
Constipation resulting from decreased gastrointestinal motility.
Nausea and vomiting commonly observed during opioid initiation.
Respiratory depression, potentially life-threatening, especially in overdose.
Pruritus and histamine-mediated flushing or itching.
Potential for acetaminophen-induced hepatotoxicity at high doses or overdose.
Confusion, mood changes, including euphoria or dysphoria.
Dry mouth from opioid and acetaminophen components.
Headache and blurred vision.
Risk of allergic reactions including rash, urticaria, or in rare cases, Stevens-Johnson syndrome.
Urinary retention due to opioid effects on detrusor muscle.
Risk of dependence, addiction, and withdrawal symptoms upon chronic use or abrupt cessation.
Increased sweating and possible serotonin syndrome in combination with serotonergic drugs.
Increased risk of sedation and respiratory compromise in elderly or debilitated patients.
Hypotension and bradycardia in some patients.

Precautions

Use caution in patients with history of substance abuse or addiction.
Monitor liver function due to risk of acetaminophen hepatotoxicity, especially with alcohol use.
Avoid concomitant use with other CNS depressants to prevent additive sedation and respiratory depression.
Adjust dose in hepatic or renal impairment to prevent accumulation and toxicity.
Careful assessment in elderly patients due to increased sensitivity to opioid effects.
Avoid use in patients with severe respiratory disorders, including asthma or sleep apnea.
Monitor for signs of serotonin syndrome when used with serotonergic agents.
Taper doses gradually to prevent withdrawal symptoms; do not stop abruptly.
Avoid concomitant use with monoamine oxidase inhibitors or within 14 days of such therapy.
Warn patients against alcohol consumption during therapy.
Educate patients and caregivers on opioid overdose symptoms and naloxone availability.
Use caution during pregnancy due to risk of neonatal opioid withdrawal syndrome.
Avoid breastfeeding due to opioid excretion in milk causing neonatal sedation or respiratory depression.
Monitor for hypersensitivity reactions and discontinue if severe skin reactions occur.
Advise patients on safe storage to prevent accidental ingestion or misuse by others.

Warnings

Risk of addiction, abuse, and misuse even at prescribed doses.
Life-threatening respiratory depression may occur, especially during initiation or dosage increases.
Do not use with alcohol, sedatives, or other CNS depressants due to fatal respiratory depression risk.
Contraindicated in patients who have used MAO inhibitors within the past 14 days.
Immediate medical attention required in case of overdose as it can be fatal.
Newborns exposed in utero risk life-threatening opioid withdrawal syndrome after birth.
Severe hepatotoxicity and death may result from acetaminophen overdose.
Potential for serious skin reactions including Stevens-Johnson syndrome.
Do not crush or chew tablets to avoid rapid release and potentially fatal dosing.
Fatal adverse reactions may result from concomitant use with other respiratory depressants.
Patients with compromised respiratory function at increased risk for severe apnea or hypoventilation.
Abrupt discontinuation may cause withdrawal symptoms; taper dose under medical supervision.
Use with caution in patients operating heavy machinery or driving until CNS effects are known.
Pregnancy Category C – potential risks to fetus and neonate must be balanced against benefits.
Keep out of reach of children to prevent accidental ingestion and fatal overdose.

Contraindication

Known hypersensitivity or allergy to oxycodone, acetaminophen, or any formulation components.
Significant respiratory depression or severe bronchial asthma in an unmonitored setting.
Known or suspected gastrointestinal obstruction, including paralytic ileus.
Concurrent use or recent (within 14 days) use of monoamine oxidase inhibitors.
Severe hepatic impairment or acute liver disease due to risk of acetaminophen toxicity.
Hypersensitivity to acetaminophen manifested as skin reactions or anaphylaxis.
Children under 12 years of age and for postoperative pain management after tonsillectomy and/or adenoidectomy in pediatric patients under 18 years.
Patients with intoxication from alcohol, hypnotics, opioids, or psychotropic drugs.
Patients with known or suspected delayed gastric emptying.
Severe renal impairment without dose adjustment and careful monitoring.

Drug Interactions

Concomitant use with other CNS depressants (e.g., benzodiazepines, barbiturates) increases risk of sedation and respiratory depression.
Interactions with monoamine oxidase inhibitors may lead to serotonin syndrome or hypertensive crisis.
Use with other opioids or opioid-containing products increases additive opioid-related adverse effects.
Medications that inhibit CYP3A4 (e.g., azole antifungals, macrolide antibiotics) can increase oxycodone plasma levels and toxicity risk.
CYP3A4 inducers (e.g., rifampin, carbamazepine) may decrease oxycodone effectiveness by increasing metabolism.
Serotonergic drugs (e.g., SSRIs, SNRIs, triptans) can increase risk of serotonin syndrome when combined with oxycodone.
Alcohol consumption may exacerbate acetaminophen hepatotoxicity and enhance CNS depression.
Anticholinergic drugs may worsen oxycodone-induced constipation and urinary retention.
Drugs affecting acetaminophen metabolism (e.g., isoniazid) may increase hepatotoxicity risk.
Use with muscle relaxants or sedatives potentiates CNS depressive effects.
Warfarin and other anticoagulants may have altered effects with concurrent acetaminophen use.
Drugs that alter gastric pH or motility may affect oxycodone absorption.
Concomitant use of serotonergic and CYP450-interacting drugs requires close monitoring.
Combination with diuretics may reduce diuretic efficacy and increase risk of hypovolemia.
Interaction with antiretroviral drugs can alter oxycodone plasma concentrations.

Preparations Of The Drug

Oral tablets containing oxycodone hydrochloride and acetaminophen with varying oxycodone strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg) combined with 325 mg acetaminophen per tablet.
Combination narcotic analgesic designed for oral administration for moderate to severe pain relief.
Controlled-release formulations not typically included; standard immediate-release tablets are used for titration and acute pain.
Available under multiple brand names including Percocet, Endocet, Roxicet, Tylox, and Xartemis XR.
Tablet formulations typically scored for ease of dose adjustment but should not be crushed or chewed.
Packaging sizes vary, commonly supplied in bottles or blister packs for outpatient use.
Not formulated for pediatric use; dosing adjustments for elderly and patients with renal/hepatic impairment are guided by medical assessment.
No injectable, transdermal, or other non-oral formulations commercially available under the Percocet brand.
Storage recommended at controlled room temperature away from moisture and heat.
Measures incorporated to minimize abuse include warning labels and patient education on safe use and disposal.